Affimed lands milestone from Roche; Puma touts new PHII data on cervical cancer
→ While Affimed $AFMD works to shake off the FDA hold on its Phase I program, the team is still making preclinical progress …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
